Comparison

ASCO Guidelines vs CARTOX

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

ASCO Guidelines

Access comprehensive cancer care guidelines and interactive tools to inform treatment decisions. This app supports healthcare providers, patients, and caregivers in implementing recommended cancer care options for various cancer types, aiming to improve the quality of care.

Highlights
  • Guideline recommendations for cancer care
  • Interactive treatment decision tools
  • Supports healthcare providers
  • Informs patients and caregivers
  • Covers various cancer types
  • Regularly updated content
Features
Read full description

The ASCO Guidelines app is your go-to tool for implementing guideline recommendations into practice. This user-friendly app provides health care providers, patients, and caregivers with the recommended cancer care options for a variety of cancer types. It also includes interactive tools to inform treatment decisions at the point of care, thus increasing the quality of care provided to patients. The ASCO app is free to members and nonmembers, kept up to date, and will continue to grow as more guidelines and tools are added.

About

CARTOX

This medical app aids clinicians in assessing and managing toxicities associated with cellular therapies, including Cytokine Release Syndrome (CRS) and Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS). It provides grading methods and treatment recommendations for healthcare professionals caring for patients undergoing immune effector cell therapy.

Highlights
  • Toxicity grading
  • CRS assessment
  • ICANS assessment
  • Treatment recommendations
  • Antimicrobial prophylaxis guidance
Features
Read full description

Cellular therapies can be associated with unique, acute toxicities which can be severe or even fatal if not identified early and treated appropriately. Cytokine Release Syndrome (CRS), the most commonly observed toxicity can range in severity from low-grade constitutional symptoms to high-grade syndrome associated with life-threatening multi-organ disfunction. Neurotoxicity, originally termed CRES (CAR-Related Encephalopathy Syndrome) and now updated to ICANS (Immune effector Cell-Associated Neurotoxicity Syndrome) is the second most-common adverse even and can occur concurrently with CRS. A multi-disciplinary working group was formed to address safety issues for patients receiving cellular therapy which led to the development of new grading methods and treatment algorithms that have been incorporated into the CARTOX mobile app. The CARTOX mobile app assists with grading toxicities, managing toxicities and assists with recommendations regarding appropriate antimicrobial prophylaxis for patients who have received immune effector cell therapy. Users are more easily able to determine if the patient is having cytokine release syndrome or neurotoxicity and to grade those toxicities. Intended audience: Clinicians (physicians, nurse practitioners, physician assistants, pharmacists, nurses) who treat/care for patients receiving immune effector cells.

Screenshots

ASCO Guidelines4 screens
CARTOX4 screens

Verdict

The call

The clearest difference is review sentiment: CARTOX at 100% against ASCO Guidelines's 57%. CARTOX also leads on rating (5.0 vs 4.8). ASCO Guidelines's advantage is update cadence (every 5 months vs every 20 months) and ratings volume (259 vs 6). On price, ads, in-app purchases and monetization model there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. Neither carries in-app purchases, so what you see is what you pay.

ReceptionRating · Positive reviews · Number of ratings

CARTOX holds the better App Store score, 5.0 against 4.8. That said, the two scores are not equally well evidenced: ASCO Guidelines has 259 ratings behind it against 6, so its average is the more settled of the two. Written reviews point the same way: 57% of ASCO Guidelines's written reviews are positive against 100% of CARTOX's.

UpkeepUpdate frequency

ASCO Guidelines ships an update every 5 months, CARTOX every 20 months. The most recent releases landed on October 24, 2026 and October 22, 2026 respectively.

Scorecard5 real differences · 5 level
ASCO Guidelines versus CARTOX: the parameters behind the verdict, then further details
ParameterASCO GuidelinesCARTOX
PriceFreeFree
Rating4.8 (259 ratings)5.0 (6 ratings) — better
Positive reviews57.1% of reviews100.0% of reviews — better
Number of ratings259 — better6
Update frequencyEvery 5 months — betterEvery 20 months
AdsNoNo
In-app purchasesNoNo
MonetizationFreeFree
DevicesiPhone, iPad, iPod — betteriPhone, iPad
Requires iOS10.0 — better26.4
Further details — not scored
Size411 MB6 MB
Age rating12+17+
DeveloperAmerican Society of Clinical OncologyMD Anderson Cancer Center

Customer experience

ASCO Guidelines

All ratings257 ratings
Positive95.3%
Neutral1.6%
Negative3.1%
Written reviews7 reviews
Positive57.1%
Neutral0.0%
Negative42.9%

CARTOX

All ratings6 ratings
Positive100.0%
Neutral0.0%
Negative0.0%
Written reviews1 reviews
Positive100.0%
Neutral0.0%
Negative0.0%

In-app purchases

None

ASCO Guidelines

No in-app purchases

None

CARTOX

No in-app purchases

Questions

Is ASCO Guidelines free?
ASCO Guidelines is free to download, with no in-app purchases.
Is CARTOX free?
CARTOX is free to download, with no in-app purchases.
Which has better reviews, ASCO Guidelines or CARTOX?
CARTOX is rated higher. ASCO Guidelines averages 4.8 out of 5 from 259 ratings, while CARTOX averages 5.0 from 6 ratings.
Do ASCO Guidelines or CARTOX have ads?
Neither ASCO Guidelines nor CARTOX shows ads.
Which is updated more often, ASCO Guidelines or CARTOX?
ASCO Guidelines ships an update every 5 months, and CARTOX every 20 months. Most recently, ASCO Guidelines was updated on October 24, 2026 and CARTOX on October 22, 2026.

Other comparisons